Aug 20, 2024
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS
Aug 06, 2024
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Aug 02, 2024
AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
Aug 01, 2024
AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS
Jun 05, 2024
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Jun 05, 2024
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
May 16, 2024
FDA APPROVES IMDELLTRA(TM) (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
May 15, 2024
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
May 09, 2024
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
May 02, 2024
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
May 01, 2024
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Mar 09, 2024
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
Feb 29, 2024
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
Feb 19, 2024
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
Feb 01, 2024
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan 03, 2024
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Feb 24, 2021
Amgen To Present At The Cowen 41st Annual Healthcare Conference
Feb 16, 2021
FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Feb 03, 2021
Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups
Feb 02, 2021
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results